To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)
To evaluate the changes in proinflammatory markers (ltd4 in urine) and eosinophil from
 peripheral blood after newly initiated montelukast therapy.
Inclusion Criteria:

 -  Allergic rhinitis symptoms: sneezing, rhinorrhea, obstruction of the nasal passages,
 itchy nose and throat, and conjunctival

 -  Male or female outpatient 20 years of age and older

 -  Patients with the following signs and symptoms of asthma and allergic rhinitis:
 history of cough, wheezing, shortness of breath, positive methacholine
 bronchoprovocation test

 Exclusion Criteria:

 -  Active, acute or chronic, pulmonary disorder (besides asthma) documented by history,
 physical examination, or chest x-ray. history of anaphylactic or hypersensitive to
 study drug

 -  Requires oral, intravenous, or intramuscular corticosteroids on daily routine basis

 -  Started on immunotherapy within six months before the pre-study visit and/or the dose
 of immunotherapy is expected to change over the course of the study

 -  Treated with montelukast within 3 months before enrollment

 -  Unable to perform acceptable, reproducible spirometry and peak flow measurement

 -  Unresolved symptoms and signs of an upper respiratory tract infection (uri) within 2
 weeks prior to visit 1